Here’s what’s in store for you in today’s issue:
🍄 Psychedelic music studio receives $4.5M in funding
🍄 How your attachment style affects your trip
🍄 First-ever study with direct psilocin
🍄 A new helmet to understand the brain
🍄 And more.
Kieran, a retired black ops vet who magically cured his neck pain with a wild DMT trip. Kieran talks about being in a constant stress state while serving and how psychedelics help him cope with ongoing PTSD.
When psilocybin is consumed, it’s metabolized into psilocin, which is the compound that produces most (or all) of the psychedelic effects.
Will the experience change if psilocin is administered directly?
Filament Health (FH) just received FDA-approval for a first-of-its kind study that will reveal the answer.
The phase I trial at the University of California San Francisco will compare the effects of psilocybin and psilocin in 20 healthy patients. Psilocybin will be administered orally, whereas psilocin will be administered both orally and sublingually, meaning it will be absorbed through tissues under the tongue.
Researchers predict that direct psilocin could result in faster onset times, greater consistency and bioavailability — with fewer side effects.
Existing treatments for post-partum depression take up to 8 weeks and often separate the mother from her baby for long periods of time, creating even more stress.
Field Trip Health (FTRP) is developing a proprietary psychedelic to change this.
The formulation, FT-104, could be administered in just one day and lasts 2-3 hours shorter than pure psilocybin. The compound leaves the mother’s system in just 24 hours, allowing her to safely breastfeed again.
FT-104 is currently in preclinical evaluation with phase I trials expected to begin in Q1 of next year.
atai Life Sciences (ATAI) developed a new compound that could help treat cognitive impairment associated with schizophrenia.
The compound, RL-007, was tested on a cohort of 8 schizophrenic patients while continuing with their antipsychotic treatments. Using brain mapping and other biomarkers, researchers found that formulation improved cognition by activating receptors linked to learning and memory.
The findings were so promising that atai decided to spend additional resources to accelerate the compound into a Phase 2a trial, which should be completed by the end of the year.
The lack of effective PTSD treatments is “a crisis,” according to the PTSD Psychopharmacology Working Group. About one in 20 people in the UK suffer from PTSD, and current treatment options are ineffective for 40% of patients.
COMPASS Pathways (CMPS) is launching a phase II trial to see if its psilocybin therapy model for treatment-resistant depression can bring relief to patients with PTSD.
The trial will assess 20 patients who experienced trauma as adults. They will be given a single dose of the psilocybin formulation followed by 12 weeks of therapy protocols.
Researchers will measure the safety of the drug as well as improvements in PTSD symptoms, functionality, and quality of life.
When patients have a positive response to music during psychedelic therapy, they’re more likely to have a mystical experience which can lead to a more effective treatment.
That’s why neuroscientist Dr. Mendel Kaelen co-founded Wavepaths – a music studio that uses AI to create customized music—on the fly—in response to a patient’s emotional state!
The implications of Wavepaths go far beyond psychedelic therapy: hospitals, birth clinics, hospice centers, and schools are showing interest in the technology. It is already being used in 30+ countries and over 5,000 practitioners await its public release.
If you’ve ever struggled with attachment anxiety in your relationships, there’s promising evidence that psilocybin could be an effective treatment:
After undergoing individual therapy, group therapy, and a single psilocybin session, a group of 18 male AIDS survivors showed significantly reduced scores for attachment anxiety – an attachment style characterized by clinginess, fear of abandonment, and difficulty trusting others.
There were no significant changes in attachment avoidance, which is characterized by repressing emotions and discomfort with close relationships.
However, high attachment anxiety scores were associated with a greater chance of mystical experiences, whereas high attachment avoidance scores were linked to grief, fear, physical distress, and paranoia during the trip.
What better way to feel more secure in your relationships than through a trip? 🤩
Lil Nas X was honoured as a visionary at the Wall Street Journal’s Innovator Awards after releasing his latest album, ‘Montero.’ Were magic mushrooms the secret behind his success?
The artist says that his first-ever mushroom trip was a pivotal moment while recording the album. The experience helped him reflect on himself and break free from feelings of self-consciousness.
“I was able to open up a lot. I was able to write actual stories about my life and put it into my music. I actually did that for the first time,” Nas explained.
The LA-based company Kernel developed a brain-imaging helmet that can track what actually happens in the brain during a psychedelic trip.
The device, Kernel Flow, was just approved by the FDA to be used in a ketamine trial sponsored by Cybin (CYBN).
Researchers will use the helmet to measure the neurological activity of 15 patients during a ketamine therapy session compared to baseline activity.
Kernel Flow is much less expensive than other brain-imaging tools and allows the patients to move freely during the session.
PharmaTher (PHRM) and Revive Therapeutics (RVV) are entering into a research agreement to develop psychedelic patches that could be used at home!
The biodegradable patches will use microneedles to deliver both micro and macrodoses of psilocybin, ketamine, MDMA, LSD, DMT, ibogaine, and mescaline.
PharmaTher is currently studying the effects of the psilocybin microdose patch, with results expected by the end of this month.
The companies aim to create a delivery method that’s safe and convenient enough for patients to administer on their own, without supervision.
PharmaTher (PHRM) and Revive Therapeutics (RVV) are entering into a research agreement to develop psychedelic patches that could be used at home!
The biodegradable patches will use microneedles to deliver both micro and macrodoses of psilocybin, ketamine, MDMA, LSD, DMT, ibogaine, and mescaline.
PharmaTher is currently studying the effects of the psilocybin microdose patch, with results expected by the end of this month.
The companies aim to create a delivery method that’s safe and convenient enough for patients to administer on their own, without supervision.
Using an AI drug discovery program, Mydecine (MYCO) successfully added a novel psilocin analogue with improved delivery and stability to its pipeline.
The AI technology synthesizes billions of drug candidates and filters them based on psychedelic-related targets such as how they bind to receptors.
Mydecine also filed a patent for nanoemulsion technology. Nanoemulsion can:
With a 61% to 39% win, Detroit became the fourth city in Michigan to widely decriminalize possession and therapeutic use of psychedelics.
Over 80% voted to establish a reparations committee that will address historical discrimination against Black communities through housing and economic development programs.
Oct 29 – Oppenheimer initiates COMPASS Pathways (CMPS) with a buy rating and $50 price target Read more…
Oct 29 – Braxia Scientific (BRAX) Announces Voting Results from the Annual General Meeting of Shareholders Read more…
Nov 1 – Blackhawk Growth’s (BLR) MindBio Therapeutics Looks to Expand Microdosing Clinical Trials Read more…
Nov 1 – Algernon Pharmaceuticals (AGN) reports positive pre-clinical data on DMT candidate to treat stroke Read more…
Nov 1 – Small Pharma (DMT) reports second quarter highlights Read more…
Nov 2 – Braxia Scientific (BRAX) Graduates First Cohort of Medical Professionals From Psilocybin-Assisted Therapy Training Program Read more…
Nov 2 – U.S. FDA Approves Nova Mentis (NOVA) Orphan Drug Application Read more…
Nov 2 – Tryp Therapeutics (TRYP) Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia Read more…
Nov 3 – Amanita Muscaria Mushroom Successfully Added to the Natural Health Products Ingredients Database (NHPID) of Canada Read more…
Nov 4 – Awakn Life Sciences (AWKN) Announces The Findings From Phase II A/B Study Are To Be Published In American Journal Of Psychiatry Read more…
Nov 5 – Novamind (NM) Reports FY2021 Financial Results and Operating Highlights Read more…
Nov 5 – NeonMind (NEON) Biosciences Named As A Top Industry Innovator In Inaugural Issue Of Psychedelia Magazine Read more…
